Is Cartesian Therapeutics Stock a good buy in 2024, according to Wall Street analysts?
The consensus among 2 Wall Street analysts covering (NASDAQ: RNAC) stock is to Buy RNAC stock.
Out of 2 analysts, 0 (0%) are recommending RNAC as a Strong Buy, 2 (100%) are recommending RNAC as a Buy, 0 (0%) are recommending RNAC as a Hold, 0 (0%) are recommending RNAC as a Sell, and 0 (0%) are recommending RNAC as a Strong Sell.
What is RNAC's revenue growth forecast for 2024-2024?
(NASDAQ: RNAC) Cartesian Therapeutics's forecast annual revenue growth rate of 36.39% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.06%.
Cartesian Therapeutics's revenue in 2024 is $26,004,000.
In 2024, RNAC is forecast to generate $332,264,565 in revenue, with the lowest revenue forecast at $107,965,740 and the highest revenue forecast at $556,563,390.
What is RNAC's forecast return on assets (ROA) for 2024-2027?
(NASDAQ: RNAC) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.
What is RNAC's Price Target?
According to 2 Wall Street analysts that have issued a 1 year RNAC price target, the average RNAC price target is $51.00, with the highest RNAC stock price forecast at $60.00 and the lowest RNAC stock price forecast at $42.00.
On average, Wall Street analysts predict that Cartesian Therapeutics's share price could reach $51.00 by Apr 10, 2025. The average Cartesian Therapeutics stock price prediction forecasts a potential upside of 184.76% from the current RNAC share price of $17.91.
What is RNAC's forecast return on equity (ROE) for 2024-2027?
(NASDAQ: RNAC) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.